These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31838080)

  • 1. Targeting SHP2 as a promising strategy for cancer immunotherapy.
    Liu Q; Qu J; Zhao M; Xu Q; Sun Y
    Pharmacol Res; 2020 Feb; 152():104595. PubMed ID: 31838080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
    Kerr DL; Haderk F; Bivona TG
    Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
    Wang Y; Mohseni M; Grauel A; Diez JE; Guan W; Liang S; Choi JE; Pu M; Chen D; Laszewski T; Schwartz S; Gu J; Mansur L; Burks T; Brodeur L; Velazquez R; Kovats S; Pant B; Buruzula G; Deng E; Chen JT; Sari-Sarraf F; Dornelas C; Varadarajan M; Yu H; Liu C; Lim J; Hao HX; Jiang X; Malamas A; LaMarche MJ; Geyer FC; McLaughlin M; Costa C; Wagner J; Ruddy D; Jayaraman P; Kirkpatrick ND; Zhang P; Iartchouk O; Aardalen K; Cremasco V; Dranoff G; Engelman JA; Silver S; Wang H; Hastings WD; Goldoni S
    Sci Rep; 2021 Jan; 11(1):1399. PubMed ID: 33446805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
    Yuan X; Bu H; Zhou J; Yang CY; Zhang H
    J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
    Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
    Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.
    Vazhappilly CG; Saleh E; Ramadan W; Menon V; Al-Azawi AM; Tarazi H; Abdu-Allah H; El-Shorbagi AN; El-Awady R
    Invest New Drugs; 2019 Apr; 37(2):252-261. PubMed ID: 29947013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A patent review of SHP2 allosteric inhibitors (2018-present).
    Petrocchi A; Ciammaichella A
    Expert Opin Ther Pat; 2024 May; 34(5):383-396. PubMed ID: 38842843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
    Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H
    Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and structure-activity relationship study of SHP2 inhibitor containing 3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene.
    Kim B; Jo S; Park SB; Chae CH; Lee K; Koh B; Shin I
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126756. PubMed ID: 31784318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
    Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
    Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
    Wu J; Zhang H; Zhao G; Wang R
    Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.
    Bobone S; Pannone L; Biondi B; Solman M; Flex E; Canale VC; Calligari P; De Faveri C; Gandini T; Quercioli A; Torini G; Venditti M; Lauri A; Fasano G; Hoeksma J; Santucci V; Cattani G; Bocedi A; Carpentieri G; Tirelli V; Sanchez M; Peggion C; Formaggio F; den Hertog J; Martinelli S; Bocchinfuso G; Tartaglia M; Stella L
    J Med Chem; 2021 Nov; 64(21):15973-15990. PubMed ID: 34714648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
    Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
    Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
    Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
    J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design potential selective inhibitors for treating cancer by targeting the Src homology 2 (SH2) domain-containing phosphatase 2 (Shp2) with core hopping approach.
    Duan YQ; Ma Y; Wang XJ; Jin YY; Wang RL; Dong WL; Xu WR; Kong DX; Wang SQ
    Protein Pept Lett; 2014 Jun; 21(6):556-63. PubMed ID: 24364859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SHP2 as a therapeutic strategy for inflammatory diseases.
    Liu Y; Yang X; Wang Y; Yang Y; Sun D; Li H; Chen L
    Eur J Med Chem; 2021 Mar; 214():113264. PubMed ID: 33582386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.